RECEPTOR.AI is a TechBio drug-discovery platform that combines machine learning, agent-based AI orchestration, and physics-based modeling to support virtual screening, SAR-driven lead optimization, and design workflows across small molecules, peptides, and induced-proximity biologic modalities.
Published Jun 25, 2026
| Starting Price | Not publicly listed; third-party reporting suggests $50k–$100k/year subscription (unverified) | Not publicly listed for enterprise licenses; training course access pricing exists but not comparable to enterprise | Not publicly listed |
| Best For | Partnered discovery and combined AI/physics workflows across modalities (small molecules, peptides, proximity) | Teams requiring a mature physics-based computational chemistry platform with enterprise tooling | Organizations using knowledge graph-driven hypothesis generation and decision support |
| Key Strength | Peer-reviewed docking publication (ArtiDock) and modular workflow positioning across modalities | Mature physics stack, broad adoption, and established enterprise operations | Knowledge graph expertise and prior application in repurposing contexts |
| Key Weakness | Limited public enterprise security/compliance artifacts and limited public user reviews; many performance claims are vendor-published | Potentially high cost and need for specialized expertise; compute requirements for some workflows | Organizational and product focus shifts reported in recent years |
—
Where RECEPTOR.AI appears to differentiate
Where competitors may excel
Customer selection dynamics (inferred)